Stories about Biotechnologie

Bosch Healthcare Solutions GmbH

Bosch and Randox: Strategic partnership brings highly multiplexing PCR to the point of care / BioMEMS technology enables fully automated, simultaneous testing for hundreds of genetic characteristics in just a few minutes

Waiblingen (ots) - - Bosch and Randox Laboratories Ltd. enter partnership for Vivalytic analysis platform to jointly invest around 150 million euros. - First test to feature novel BioMEMS technology will be a highly multiplexing sepsis IVD grade test. Bosch has agreed on a strategic partnership with Randox ...

ARTCLINE GmbH

ARTCLINE successfully completes capital increases of EUR 4.4 million

Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...

Polaroid Therapuetics

Polaroid Therapeutics completes pre-clinical milestones in the development of superior antimicrobial technology for acute and chronic wounds

Bern, Switzerland (ots/PRNewswire) - - Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats - The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and ...

Biomay AG

Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy

SHL Medical

SHL Medical further strengthens vertical capabilities with the acquisition of US manufacturer Superior Tooling Inc.

Medison Pharma

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

Zug, Switzerland (ots/PRNewswire) - - Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory ...

BioVaxys Technology Corp.

BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition

Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a non-binding Letter of Intent ("LOI") to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio of discovery, preclinical development, and Phase II clinical study ...

BioVaxys Technology Corp.

BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare

Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that as part of BioVaxys' efforts to refocus on immunotherapeutics, Biovaxys and Procare Health ("Procare") have jointly and amicably agreed to terminate the US Distribution Agreement for Papilocare and Immunocaps. The partnership ...

Biomay AG

Biomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services

Medison Pharma; Ipsen

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Zug, Switzerland and Paris (ots/PRNewswire) - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, ...

Gerresheimer AG

Gerresheimer awarded EcoVadis Gold status again

Duesseldorf (ots) - - Gerresheimer among the top 5% of assessed businesses - Total score increases to 72/100 points - Status demonstrates consistent implementation of CSR strategy Gerresheimer, an innovative provider of systems and solutions and a global partner for the pharma, biotech, and cosmetic industries, has once again been awarded Gold status by the ratings agency EcoVadis. EcoVadis assesses the performance of ...

Acousia Therapeutics GmbH

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...

Acousia Therapeutics GmbH

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...

Gerresheimer AG

Gerresheimer at CPHI: focus on high-value solutions and sustainability

Duesseldorf (ots) - - Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy support - High-quality ready-to-fill solutions for biopharmaceuticals, cell and gene therapy - EcoDesign and environmentally friendly packaging options ensure greater sustainability Gerresheimer, an innovative system and solution ...

Takeda Pharma Vertrieb GmbH & Co. KG

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...

R-Biopharm AG

2

R-Biopharm AG announces personnel changes in the Board of Directors and restructuring

Lysando AG

Artilysin® - A Groundbreaking "Green Pharma" Solution

REVEAL GENOMICS, S.L.

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL

Barcelona, Spain (ots/PRNewswire) - - HER2DX® pCR-score was significantly associated with pathological complete response in patients with HER2+ breast cancer treated with trastuzumab and pertuzumab, with or without chemotherapy. - HER2DX® risk-score identified 85% of patients with an invasive disease event as ...

Berlin Cures

Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth / Phase II study for BC 007 in the indication Long COVID to start in June

CROMA-PHARMA GmbH

Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China

Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active ...

Debiopharm International SA

DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER

Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...

Debiopharm International SA

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS

Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...

Lysando AG

Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows

Hovione

Hovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery

Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that ...

eleva GmbH

Björn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development

Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...

Debiopharm International SA

DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM

Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...

lino Biotech AG

Miltenyi Biotec acquires biosensor company lino Biotech

Zurich (ots) - lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy ...

R-Biopharm AG

Blood Donation Day at R-Biopharm: Employees Help Save Lives

biomindz Standortentwicklungsgesellschaft Mainz GmbH i.G.

Newly established company to promote Mainz as hub for life science and biotechnology now operational and supporting the city of Mainz

CO.DON GmbH

CO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg

Leipzig / Teltow (ots) - CO.DON continues business operations as a GmbH (limited liability company) With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a ...